Nuvectis Pharma (NVCT)
Develops licensed small-molecule programs across complement disease and kinase-targeted oncology.
$24.00
At close+0.94 (+4.08%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions63 holders · as of Mar 31, 2026 | 13.87% | 4.52M shares | |
| Insiders9 holders · as of Aug 5, 2026 | 42.70% | 13.91M shares | |
| Otherremainder | 43.43% | 14.15M shares |
32.58M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (32.58M in the company's Sep 3, 2026 report, 26.54M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
63 holders · 4.52M shares · 17 new positions · 38 increased · 9 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 764.4K | 2.35% | −18.4K | May 13, 2026 |
| Vanguard Capital Management LLC | 659.9K | 2.03% | +659.9Knew | May 15, 2026 |
| Iridian Asset Management LLC/CT | 651.8K | 2.00% | +65.4K | Apr 24, 2026 |
| Occam Crest Management LP | 407.1K | 1.25% | +27.1K | May 15, 2026 |
| Geode Capital Management, LLC | 384.1K | 1.18% | +20.1K | May 15, 2026 |
| Baldwin Brothers LLC/MA | 378.6K | 1.16% | −11.0K | Apr 14, 2026 |
| State Street Corp | 166.5K | 0.51% | +11.9K | May 15, 2026 |
| Northern Trust Corp | 124.2K | 0.38% | +7.8K | May 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 30, 2026 | Ron Bentsurdirector, 10 percent owner, officer: Chairman & CEO | Purchase | 12,500 | $20.00 | 3,688,424 |
| Jun 30, 2026 | Marlio Charles Mosseri10 percent owner | Purchase | 50,000 | $18.32 | 3,186,576 |
| Nov 5, 2025 | Matthew L. Kaplandirector | Purchase | 11,000 | $5.84 | 124,760 |
| Nov 5, 2025 | Juan Sanchezdirector | Purchase | 13,000 | $5.79 | 78,150 |
| Nov 5, 2025 | Ron Bentsurdirector, 10 percent owner, officer: Chairman & CEO | Purchase | 5,000 | $5.72 | 3,525,924 |
| Oct 23, 2025 | Marlio Charles Mosseri10 percent owner | Purchase | 46,900 | $6.06 | 3,028,706 |
| Oct 24, 2025 | Marlio Charles Mosseri10 percent owner | Purchase | 35,034 | $6.15 | 3,063,740 |
| Oct 27, 2025 | Marlio Charles Mosseri10 percent owner | Purchase | 72,836 | $6.28 | 3,136,576 |
CongressHouse and Senate disclosures
Not reported.